<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02356991</url>
  </required_header>
  <id_info>
    <org_study_id>HR-FMTN- Ⅱ-NSCLC-MON</org_study_id>
    <nct_id>NCT02356991</nct_id>
  </id_info>
  <brief_title>A Study of Famitinib in Patients With Advanced Non-squamous and Non-Small Cell Lung Cancer (NSCLC)</brief_title>
  <official_title>A Randomized,Double-Blind, Placebo-Controlled, Multicenter, Phase II Study of Famitinib in Patients With Advanced Non-squamous and Non-Small Cell Lung Cancer (NSCLC)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jiangsu HengRui Medicine Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Sun Yat-sen University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shanghai Pulmonary Hospital, Shanghai, China</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Jiangsu HengRui Medicine Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Famitinib is a tyrosin-inhibitor agent targeting at c-Kit, VEGFR2, PDGFR, VEGFR3, Flt1 and&#xD;
      Flt3. Phase I study has shown that the toxicity is manageable.&#xD;
&#xD;
      The purpose of this study is to evaluate the efficacy and safety profile of Famitinib in&#xD;
      patients with Advanced Non-squamous and Non-Small Cell Lung Cancer (NSCLC).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Suspended</overall_status>
  <why_stopped>
    sponsor decides to suspend this trial&#xD;
  </why_stopped>
  <start_date type="Actual">December 2014</start_date>
  <completion_date type="Anticipated">June 2020</completion_date>
  <primary_completion_date type="Anticipated">June 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progress free survival (PFS)</measure>
    <time_frame>1.5 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate (ORR)</measure>
    <time_frame>1 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Control Rate (DCR)</measure>
    <time_frame>1 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life</measure>
    <time_frame>28-day cycle visit until disease progress</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">137</enrollment>
  <condition>Non-Small Cell Lung Cancer (NSCLC)</condition>
  <arm_group>
    <arm_group_label>Famitinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Famitinib 25 mg qd p.o., 4 weeks per cycle.The treatment continued until disease progression or intolerable toxicity happened or patients withdrawal of consent.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo 25 mg qd p.o., 4 weeks per cycle.The treatment continued until disease progression or intolerable toxicity happened or patients withdrawal of consent.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Famitinib</intervention_name>
    <arm_group_label>Famitinib</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  1.Age: 18-70;&#xD;
&#xD;
          -  2.Advanced (IV phase)non squamous NSCLC confirmed by pathology, with measurable&#xD;
             lesions (tumour lesions ≥10mm in longest diameter, malignant lymph nodes ≥15mm in&#xD;
             short axis, scanning layer ≤ 5 mm, measurable lesions not received locoregional&#xD;
             theraphy ,such as radiotherapy or frozen therapy);&#xD;
&#xD;
          -  3.Previously treated with EGFR inhibitors or chemotherapy,second line or above&#xD;
             treatment failure:&#xD;
&#xD;
               -  a.for EGFR wild type, second line or above treatment failure(at least previously&#xD;
                  treated with platinum-based chemotherapy)&#xD;
&#xD;
               -  b.for EGFR mutation type, third line or above treatment failure(at least&#xD;
                  previously treated with Platinum-based chemotherapy and EGFR inhibitors)&#xD;
&#xD;
          -  4.ECOG Performance Status of 0 or 1;&#xD;
&#xD;
          -  5.Life expectancy of at least 3 months;&#xD;
&#xD;
          -  6.Damage caused by other anti-tumor therapy has been restored, the nitroso or&#xD;
             mitomycin treatment interval ≥ 6 weeks; other cytotoxic drugs, radiotherapy or surgery&#xD;
             for ≥ 4 weeks; EGFR molecular targeted drugs for ≥ 2 weeks;&#xD;
&#xD;
          -  7.Participants have inadequate organ and marrow function as defined below:&#xD;
&#xD;
               -  Hemoglobin ≥ 90g/L ( no blood transfusion in 2 weeks)&#xD;
&#xD;
               -  Absolute neutrophil count (ANC) ≥ 1.5×10^9/L&#xD;
&#xD;
               -  PLT ≥ 80×10^9/L&#xD;
&#xD;
               -  Bilirubin &lt; 1.25 × ULN&#xD;
&#xD;
               -  ALT &lt; 2.5 × ULN&#xD;
&#xD;
               -  AST &lt; 2.5 × ULN&#xD;
&#xD;
               -  serum creatinine &lt; 1.25 × ULN, and endogenous Cr clearance &gt; 45&#xD;
                  ml/min(Cockcroft-Gault Formula)&#xD;
&#xD;
               -  cholesterol ≤ 1.5×ULN and triglyceride≤ 2.5 × ULN&#xD;
&#xD;
               -  LVEF≥ LLN by Color Doppler Ultrasonography&#xD;
&#xD;
          -  8.Female: Child bearing potential, a negative urine or serum pregnancy test result 7&#xD;
             days before initiating famitinib.All subjects who are not surgically sterile or&#xD;
             postmenopausal must agree and commit to the use of a reliable method of birth control&#xD;
             for the duration of the study and for 8 weeks after the last dose of test article.&#xD;
             Male: All subjects who are not surgically sterile or postmenopausal must agree and&#xD;
             commit to the use of a reliable method of birth control for the duration of the study&#xD;
             and for 8 weeks after the last dose of test article;&#xD;
&#xD;
          -  9.Ability to understand and willingness to sign a written informed consent. Good&#xD;
             compliance with follow-up visits.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  1.Squamous cell carcinoma (including adenosquamous carcinoma, undifferentiated&#xD;
             carcinoma); small cell lung cancer (lung cancer including small cell carcinoma and&#xD;
             non-small cell hybrid);&#xD;
&#xD;
          -  2.Known brain metastases, spinal cord compression, cancer meningitis, or screening CT&#xD;
             or MRI examination revealed brain or leptomeningeal disease&#xD;
&#xD;
          -  3.Patients with hypertension using combination therapy (systolic blood pressure&gt; 140&#xD;
             mmHg, diastolic blood pressure&gt; 90 mmHg). Patients with more than Class I, myocardial&#xD;
             ischemia or myocardial infarction, arrhythmia (including QT interval ≥ 450ms for male&#xD;
             and 470ms for female) and class II cardiac dysfunction,according to NCI-CTC AE 4.0;&#xD;
&#xD;
          -  4.Variety of factors that affect the oral medication (such as inability to swallow,&#xD;
             gastrointestinal resection, chronic diarrhea and intestinal obstruction);&#xD;
&#xD;
          -  5.Coagulation abnormalities (PT or PT-INR &gt; 1.5 ULN, and APTT &gt; 1.5 ULN), bleeding&#xD;
             tendency (eg, active peptic ulcer) or are receiving thrombolytic or anticoagulant&#xD;
             therapy;&#xD;
&#xD;
          -  6.Distance between tumours lesions and major blood vessels with radiographical&#xD;
             evidence (CT or MRI) ≥5mm.&#xD;
&#xD;
          -  7.Pulmonary hemorrhage/ bleeding event ≥ CTCAE gr. 1 （including Hemoptysis≥2.5ml or&#xD;
             half teaspoon）within four weeks of the first dose of the study drug; Any other&#xD;
             hemorrhage/ bleeding event ≥ CTCAE gr. 2 within four weeks of the first dose of the&#xD;
             study drug;&#xD;
&#xD;
          -  8.Long-term untreated wounds or fractures;&#xD;
&#xD;
          -  9.Thrombotic or embolic venous or arterial events such as cerebrovascular accident&#xD;
             (including transient ischemic attacks), deep vein thrombosis or pulmonary embolism&#xD;
             within the 12 months prior to the first dose of study drug;&#xD;
&#xD;
          -  10.Urine protein ≥ + + and confirmed the 24-hour urinary protein&gt;1.0 g;&#xD;
&#xD;
          -  11.Application of anticoagulants or vitamin K antagonists such as warfarin, heparin or&#xD;
             its analogues; If the prothrombin time international normalized ratio (INR) ≤ 1.5,&#xD;
             with the purpose of prevention, the use of small doses of warfarin (1mg orally, once&#xD;
             daily) ，low-dose heparin (0.6~1.2 ×10^8 U daily) low-dose aspirin (less than 100mg&#xD;
             daily) is allowed;&#xD;
&#xD;
          -  12.Preexisting thyroid dysfunction, even using medical therapy, thyroid function&#xD;
             cannot maintain in the normal range;&#xD;
&#xD;
          -  13.Pre-existing ascites and/or clinically significant pleural effusion;&#xD;
&#xD;
          -  14.Active hepatitis C and/or B infection;&#xD;
&#xD;
          -  15.Abuse of psychiatric drugs or dysphrenia;&#xD;
&#xD;
          -  16.Participated in other anti-cancer clinical trials within four weeks;&#xD;
&#xD;
          -  17.Prior therapy with VEGFR inhibitor，except Bevacizumab (Avastin);&#xD;
&#xD;
          -  18.Past or suffering from other cancer, but other than cure basal cell carcinoma and&#xD;
             cervical carcinoma in situ.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Li Zhang, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cancer Hospital of Guangzhou Sun Yat-sen University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cancer Hospital of Guangzhou Sun Yat-sen University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510060</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tongji University Affiliated Shanghai Pulmonary Hospital</name>
      <address>
        <city>Shanghai</city>
        <zip>200433</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>January 16, 2015</study_first_submitted>
  <study_first_submitted_qc>February 2, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 6, 2015</study_first_posted>
  <last_update_submitted>October 31, 2019</last_update_submitted>
  <last_update_submitted_qc>October 31, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 4, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Famitinib</keyword>
  <keyword>Phase II</keyword>
  <keyword>NSCLC</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

